Novocure Ltd buy melinda
Start price
06.03.18
/
50%
€19.62
Target price
17.04.18
€21.29
Performance (%)
8.85%
End price
17.04.18
€21.35
Summary
This prediction ended on 17.04.18 with a price of €21.35. The BUY prediction by melinda finished with a performance of 8.85%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novocure Ltd | -3.288% | -3.288% | -53.443% | -85.527% |
| iShares Core DAX® | -1.875% | 2.861% | 18.863% | 63.672% |
| iShares Nasdaq 100 | -2.177% | 0.048% | 3.956% | 109.562% |
| iShares Nikkei 225® | -0.867% | 6.987% | 21.062% | 54.912% |
| iShares S&P 500 | -1.253% | 1.248% | 2.246% | 69.801% |
Comments by melinda for this prediction
In the thread Novocure Ltd diskutieren
Biotechnologie und Medizintechnik SecteurRecherche Agenda 14/05 Ergebnisse Veröffentlichung
$ 21.75
+0,15 (+ 0,69%) Tumor Behandlung Fields (TTFields) - PANOVA 3 Bauchspeicheldrüsenkrebs
Phase 3 2022 2022.12.31 Phase-3-Daten im Jahr 2022 fällig.